Avacta Group PLC Notice of Results (1561L)
September 09 2021 - 2:00AM
UK Regulatory
TIDMAVCT
RNS Number : 1561L
Avacta Group PLC
09 September 2021
9 September 2021
Avacta Group plc
("Avacta" or "the Group")
Notice of Results and Investor Presentation
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical
company developing innovative cancer therapies and powerful
diagnostics based on its proprietary Affimer(R) and pre|CISION(TM)
platforms, will announce its unaudited interim results for the six
months ended 30 June 2021 on Thursday, 30 September 2021.
Investor webinar
An investor webinar presentation by Alastair Smith, Chief
Executive Officer and Tony Gardiner, Chief Financial Officer, will
take place at 10:30am BST on Thursday, 30 September 2021.
The webinar is open to all existing and potential investors and
will consist of a presentation followed by a Q&A session, held
on the Investor Meet Company platform. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 9am the
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free and then
click "Add to meet" Avacta Group via the following link to join the
webinar:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
Investors who already follow Avacta Group plc on the Investor
Meet Company platform will automatically be invited.
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414 0452
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited (Nomad Tel: +44 (0) 207 710 7600
and Broker) www.stifel.com
Nicholas Moore / Nick Adams / Fred
Walsh / Ben Maddison
FTI Consulting (Financial Media Tel: +44(0) 203 727 1000
and IR) Avacta.LS@fticonsulting.com
Simon Conway / Stephanie Cuthbert
Zyme Communications (Trade and Tel: +44 (0)7891 477 378
Regional Media) lily.jeffery@zymecommunications.com
Lily Jeffery
About Avacta Group plc - https://www.avacta.com
Avacta Group is developing novel cancer immunotherapies and
powerful diagnostics based on its two proprietary platforms -
Affimer(R) biologics and pre|CISION(TM) tumour targeted
chemotherapies.
The Affimer(R) platform is an alternative to antibodies derived
from a small human protein. Despite their shortcomings, antibodies
currently dominate markets, such as diagnostics and therapeutics,
worth in excess of $100bn. Affimer technology has been designed to
address many of these negative performance issues, principally: the
time taken to generate new antibodies and the reliance on an
animal's immune response; poor specificity in many cases; their
large size, complexity and high cost of manufacture.
Avacta's pre|CISION(TM) targeted chemotherapy platform releases
active chemotherapy in the tumour, which limits the systemic
exposure that causes damage to healthy tissues, and thereby
improves the overall safety and therapeutic potential of these
powerful anti-cancer treatments.
The Group comprises two divisions: The therapeutics development
activities are based in Cambridge, UK and the Group is generating
near-term revenues from Affimer reagents for diagnostics,
bioprocessing and research, through a separate diagnostics business
unit based in Wetherby, UK.
Avacta's Diagnostics Division works with partners world-wide to
develop bespoke Affimer(R) reagents for third party products. The
Group is also developing an in-house pipeline of Affimer-based
diagnostic assays including the AffiDX(R) SARS-CoV-2 Lateral Flow
Rapid Antigen Test and AffiDX(R) BAMS(TM) SARS-CoV-2 Assay in
partnership with Adeptrix Inc.
Avacta's Therapeutics Division is working to deliver a more
tolerable and durable treatment response for oncology patients who
do not respond to existing immunotherapies. By combining its two
proprietary platforms the Group is building a wholly owned pipeline
of clinically differentiated cancer therapies, aiming to extend the
therapeutic benefits to all cancer patients. In 2021 Avacta
transitioned to become a clinical stage biopharmaceutical company,
commencing a phase I first-in-human, open label, dose-escalation
and expansion study of AVA6000, a pro-doxorubicin, the Group's lead
pre|CISION(TM) prodrug, in patients with locally advanced or
metastatic selected solid tumours.
Avacta has established drug development partnerships with pharma
and biotech, including a research collaboration with ModernaTX,Inc.
(formerly Moderna Therapeutics Inc.), a multi-target deal with LG
Chem worth up to $400m, a joint venture in South Korea with
Daewoong Pharmaceutical focused on cell and gene therapies
incorporating Affimer immune-modulators, a partnership with ADC
Therapeutics to develop Affimer-drug conjugates and a collaboration
with Point Biopharma to develop radiopharmaceuticals based on the
pre|CISION(TM) platform. Avacta continues to actively seek to
license its proprietary platforms in a range of therapeutic
areas.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSAFDAEFSEFU
(END) Dow Jones Newswires
September 09, 2021 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024